Biotechnology Newswire
1 - Elan Corporation plc Announces Pricing of New 2016 Senior Notes
DUBLIN-(Business Wire)-September 29, 2009 - Elan Corporation, plc ("Elan") today announced the pricing of the offering of US$625 million aggregate principal amount of senior notes due 2016 (“New Notes”) by its wholly-owned subsidiaries, Elan Finance public limited company and Elan Finance...
2 - Idaho Technology Expands Its High Resolution Melting Patent Portfolio
SALT LAKE CITY-(Business Wire)-September 29, 2009 - Idaho Technology’s patent portfolio continues to grow as the U.S. Patent and Trademark Office granted the company U.S. Patent No. 7,582,429 relating to methods of performing genetic analysis in the presence of a double-stranded nucleic acid...
3 - JMP Securities Healthcare Conference to Be Held in New York
SAN FRANCISCO-(Business Wire)-September 29, 2009 - JMP Group Inc. (NYSE:JMP), an investment banking and alternative asset management firm, announced today that JMP Securities will host the fourth annual JMP Securities Healthcare Focus Conference at The New York Palace hotel in New York on Monday...
4 - AZBio Announces Recipients of 2009 Awards
PHOENIX-(Business Wire)-September 29, 2009 - AZBio (Arizona BioIndustry Association) announced the winner of the association's annual awards, which were presented at the 2009 AZBio Awards Dinner, the largest annual gathering of Arizona's bioscience community, on Thursday, September 24th at the...
5 - Celera to Webcast Presentation at JMP Securities 2009 Healthcare Conference
ALAMEDA, Calif.-(Business Wire)-September 29, 2009 - Celera Corporation (NASDAQ:CRA) announced today that it will webcast its presentation at the JMP Securities 2009 Healthcare conference on Tuesday, October 6, 2009. The live webcast is scheduled to begin at 10:00 am ET. Ugo DeBlasi, Chief Financial...
6 - SATAI Announces $1.045 Million Emerging Technology Fund Investment in Azaya Therapeutics, Inc.
SAN ANTONIO-(Business Wire)-September 29, 2009 - SATAI (www.satai.us) and the South Texas Regional Center of Innovation and Commercialization (www.strcic.com) today announced an investment of $1.045 million in Azaya Therapeutics, Inc. through the Texas Emerging Technology Fund (ETF) for the...
7 - SeraCare Life Sciences Awarded Multiple Contracts from the CDC and NIH to Support HIV Research and the Accuracy of HIV Testing
MILFORD, Mass.-(Business Wire)-September 29, 2009 - SeraCare Life Sciences, Inc. (NASDAQ: SRLS) today announced that the Company has been awarded two new contracts from the Centers for Disease Control (CDC) and the National Institutes of Health (NIH) and that a third existing contract has been...
8 - Intelligent Enterprise Solutions, Inc., is Hosting 3rd qPCR Symposium USA on 9-12 November at Millbrae, CA
SANTA CLARA, Calif.-(Business Wire)-September 29, 2009 - qPCR (Real-time quantitative PCR) has rapidly developed as the prime technology to detect and quantify nucleic acids in complex samples. It is used in the life science industry, healthcare, diagnostics, forensics, food, feed, agriculture, air...
9 - Girindus Not Affected by Solvay's Decision to Sell Pharmaceuticals Sector
BERGISCH GLADBACH, Germany & CINCINNATI, Ohio-(Business Wire)-September 29, 2009 - Girindus, a leading service provider to the pharmaceutical industry and a dedicated manufacturer of therapeutic oligonucleotides, announces that Girindus Group is not affected by Solvay's decision to sell its...
10 - Personalized, Gene-Based Risk Testing For Lung Cancer Gives New Tool To Help Smokers Quit
PHILADELPHIA-(Business Wire)-September 29, 2009 - Smokers who learn their personal risk of lung cancer through gene-based risk assessment are more likely to be motivated to quit their habit, according to Dr. W. Jeffrey Allard, clinical affairs director of Synergenz Bioscience Ltd. The...
11 - Clinical Data, Inc. to Present at the JMP Securities Healthcare Focus Conference
NEWTON, Mass.-(Business Wire)-September 29, 2009 - Clinical Data, Inc. (NASDAQ: CLDA), today announced that Drew Fromkin, President and Chief Executive Officer, will be presenting a corporate overview at the Fourth Annual JMP Securities Healthcare Focus Conference. Clinical Data's presentation...
12 - Cubist Pharmaceuticals Announces Enhanced Careers Section of Corporate Website
LEXINGTON, Mass.-(Business Wire)-September 29, 2009 - Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) is pleased to announce the re-launch of its corporate website and the introduction of the newly created Careers section. Our goal is to enhance the job seekers’ experience with both active and...
13 - ABL and Evivar Medical Enter into Agreements to Form a Global Strategic Partnership and IP Cross-Licensing for Disease Management and Personalized Healthcare of Hepatitis B and HIV Infections
LUXEMBOURG & MELBOURNE, Australia-(Business Wire)-September 29, 2009 - ABL, S.A. and Evivar Medical Pty Ltd today announced the completion of agreements to cross-licence their respective intellectual property portfolios and to form strategic alliances based on the use of their proprietary...
14 - VeriChip Corporation and RECEPTORS LLC Announce Further Details of Development Plan for Virus Triage Detection System for H1N1 Virus
DELRAY BEACH, Fla. & CHASKA, Minn.-(Business Wire)-September 29, 2009 - VeriChip Corporation (“VeriChip”) (NASDAQ: CHIP) and its development partner RECEPTORS LLC, a technology company whose AFFINITY by DESIGN™ chemistry platform can be applied to the development of selective binding...
15 - VeriChip Corporation Announces $10 Million Financing Commitment
DELRAY BEACH, Fla.-(Business Wire)-September 29, 2009 - VeriChip Corporation ("VeriChip" or the "Company") (NASDAQ: CHIP) today announced it has entered into a definitive agreement for a $10,000,000 investment commitment with Optimus Technology Capital Partners, LLC, or Optimus. The Company...
16 - RegeneRx’s Tβ4 Significantly Improves Functional Recovery in Multiple Sclerosis Animal Model
BETHESDA, Md.-(Business Wire)-September 29, 2009 - REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) announced today that researchers at the Henry Ford Health System in Detroit, Michigan, demonstrated for the first time that Tβ4 treatment of EAE (experimental autoimmune encephalomyelitis – an...
17 - Court Rules in Favor of Bard in Class Action Lawsuit
MURRAY HILL, N.J.-(Business Wire)-September 29, 2009 - C. R. Bard, Inc. (NYSE: BCR) today announced that the U.S. District Court, Eastern District of Missouri, has granted Bard's summary judgment motion and dismissed with prejudice all counts in the previously-disclosed class action lawsuit entitled...
18 - LifeCycle Pharma Announces Positive Results from a 12 Month Extension Phase of the Phase 2 Clinical Study of LCP-Tacro™ Once Daily in Stable Liver Transplant Patients
HØRSHOLM, Denmark-(Business Wire)-September 29, 2009 - LifeCycle Pharma A/S (CSE:LCP) today announced positive results from a completed 12 month extension phase of the Phase 2 clinical study of LCP-Tacro tablets in stable liver transplant patients. LCP-Tacro is a once daily immunosuppression drug...
19 - PolyMedix Initiates Dosing in Phase 1B Clinical Study of Novel Anticoagulant Antagonist Compound
RADNOR, Pa.-(Business Wire)-September 29, 2009 - PolyMedix, Inc. (OTC BB: PYMX, http://polymedix.com), an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has initiated dosing and commenced a...
20 - Top Life Sciences Attorney to Join Intrexon as Chief Legal Officer
BLACKSBURG, Va.-(Business Wire)-September 29, 2009 - Intrexon Corporation, a privately held life sciences company focused on modular DNA control systems for biotherapeutics and other industry sectors, today announced the appointment of Asher M. Rubin as Executive Vice President, Chief Legal Officer...
21 - CPRIT Announces Release of Two Prevention Funding Opportunities
AUSTIN, Texas-(Business Wire)-September 29, 2009 - The Cancer Prevention and Research Institute of Texas (CPRIT) has released its first two cancer prevention requests for applications (RFA) just six weeks after Rebecca Garcia, Ph.D. joined CPRIT’s leadership team as chief prevention officer...
22 - New APCER Pharma Solutions, Inc. Webinar Offers Pharmaceutical Companies Actionable Advice on Managing 2010 FDA Drug Safety Initiatives
PRINCETON, N.J.-(Business Wire)-September 29, 2009 - APCER Pharma Solutions, Inc.’s (“APCER”) important new webinar will feature an enlightening approach to help prepare pharmaceutical companies for 2010 FDA drug safety and pharmacovigilance initiatives. The event is free of charge. Title...
23 - SafeStitch Medical, Inc. Appoints Dr. Chao Chen to Board of Directors
MIAMI-(Business Wire)-September 29, 2009 - SafeStitch Medical, Inc. (OTCBB: SFES) announced today that, on September 24, 2009, the Company’s Board of Directors appointed Chao C. Chen, Ph.D. to fill the vacant seat on the Company’s Board. “We are very excited to welcome Dr. Chen, a former...
24 - Impulse Monitoring to Provide Neuromonitoring Support to Vanderbilt University Medical Center
COLUMBIA, Md.-(Business Wire)-September 29, 2009 - Impulse Monitoring, Inc. (IMI), a leading provider of intraoperative neurophysiological monitoring (IONM) services to hospitals, today announced that it has signed an agreement with the Vanderbilt University Medical Center (VUMC), Nashville, TN...
25 - Metabolomics Used to Discover Biomarkers for Periodontal Disease
RESEARCH TRIANGLE PARK, N.C.-(Business Wire)-September 29, 2009 - Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, today announced a new study has been published identifying biomarkers for periodontitis and gingivitis. Co-authored by scientists at...
26 - Luminex Corporation Hosts Seventh Annual Planet xMAP Europe
Luminex Corporation (NASDAQ: LMNX), the worldwide leader in multiplexed solutions, today announced that it will host Planet xMAP Europe 2009, its annual European multiplexing technology symposium, October 7-8, 2009, at Beurs van Berlage in Amsterdam. The program for Planet xMAP Europe 2009...
27 - Bio Japan 2009: The Biggest Biotechnology Event in Japan.
YOKOHAMA, Japan-(Business Wire)-September 29, 2009 - We would like to thank you sincerely for your understanding and ongoing cooperation for BioJapn. With your wholehearted support, BioJapan has been progressing successfully in both its contents and scale every year. This year, we are aiming to...
28 - Pluristem Therapeutics Has Been Selected to Present at The Israeli Presidential Conference 2009: Facing Tomorrow, Based on the Company’s Proprietary Technology and the Potential to Shape The Future of the Stem Cell Industry
HAIFA, Israel-(Business Wire)-September 29, 2009 - Pluristem Therapeutics Inc. (NasdaqCM: PSTI) (DAX: PJT) today announced it has been selected as one of the Israeli innovators in the stem cell field to present at The Israeli Presidential Conference 2009: Facing Tomorrow – Tomorrow's Industries...
29 - The Cleveland Clinic Recognizes AxioMed Spine Corporation
GARFIELD HEIGHTS, Ohio-(Business Wire)-September 29, 2009 - At the 6th Annual Cleveland Clinic Innovator Awards dinner, AxioMed Spine Corporation (www.axiomed.com) was awarded the Ferchill Partner Award for the company’s medical innovation and economic impact on the community. The Cleveland Clinic...
30 - Innovex and Healthcare at Home Announce Joint Venture
BRACKNELL, UK & BURTON-UPON-TRENT, UK-(Business Wire)-September 29, 2009 - Innovex, a Quintiles company, and Healthcare at Home today announced that they have agreed to form an innovative healthcare joint venture in Europe, named Healthcare at Home Europe. Healthcare at Home Europe, a separate...
31 - Vitae Receives $8 Million Payment from Boehringer Ingelheim for Achievement of 11beta-HSD-1 Program Milestone
FORT WASHINGTON, Pa.-(Business Wire)-September 29, 2009 - Vitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced that it has earned an $8 million milestone payment from Boehringer Ingelheim for achievement of a performance milestone in their...
32 - Seattle Genetics to Present at JMP Securities Healthcare Focus Conference
BOTHELL, Wash.-(Business Wire)-September 29, 2009 - Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that company management will present at the Fourth Annual JMP Securities Healthcare Focus Conference on Monday, October 5, 2009, at 8:30 a.m. Eastern Time. The conference is being held at The...
33 - Plexxikon Announces First Patient Dosed in First of Two Pivotal Trials of PLX4032 for Metastatic Melanoma
BERKELEY, Calif.-(Business Wire)-September 29, 2009 - Plexxikon Inc. announces that enrollment has been initiated and the first patient has been treated in the first of two pivotal trials of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly selective drug...
34 - Sermo Panels Tap into Social Media Platform for On-Demand Physician Opinions
CAMBRIDGE, Mass.-(Business Wire)-September 29, 2009 - Sermo, the largest online community exclusively for physicians, today formally launched Sermo Panels™ - a new on-demand offering enabling businesses to engage with and gather insights from physicians in a private online workspace. Sermo Panels...
35 - MabCure Inc. Produces Monoclonal Antibodies against Colorectal Cancer
HASSELT, Belgium-(Business Wire)-September 29, 2009 - MabCure, Inc. (“MabCure”), a biotechnology company that has developed a series of highly specific monoclonal antibodies (MAbs) to combat various types of cancers, has reached another development milestone, with the creation of its MAbs...
36 - Novelos Therapeutics Announces $1 Million NIH Grant to MGH to Study NOV-002 and NOV-205 In Animal Models of Radiation-Induced Lung Injury
NEWTON, Mass.-(Business Wire)-September 29, 2009 - Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the Massachusetts General Hospital (MGH), in collaboration with Novelos, was awarded...
37 - Cerus to Present Proposal for INTERCEPT Platelet US Phase III Clinical Trial at November BPAC Meeting
CONCORD, Calif.-(Business Wire)-September 29, 2009 - Cerus Corporation (NASDAQ:CERS) announced today that it will present the proposed design for a U.S. Phase III clinical trial of the INTERCEPT Blood System for platelets at the upcoming November meeting of the FDA's Blood Products Advisory...
38 - Life Technologies Foundation Awards $1.7 Million in Grants to Advance Science
CARLSBAD, Calif.-(Business Wire)-September 29, 2009 - The Life Technologies Foundation, a non-profit arm of Life Technologies Corporation (NASDAQ: LIFE) dedicated to advancing science education and scientific discovery, has awarded approximately $1.7 million in new grants that include the creation...
39 - TruTouch Technologies Names Dr. Richard D. Gill as President and Chief Executive Officer
ALBUQUERQUE, N.M.-(Business Wire)-September 29, 2009 - TruTouch Technologies, a pioneer in non-invasive intoxication measurement systems, today named longtime industry executive Dr. Richard D. Gill as President and Chief Executive Officer. Dr. Gill joins TruTouch after nearly 30 years of strategic...
40 - BSD Medical Corporation Sells Hyperthermia System to University of California, San Francisco Medical Center
SALT LAKE CITY-(Business Wire)-September 29, 2009 - BSD Medical Corporation (NASDAQ: BSDM) (www.BSDMedical.com) announced today that the University of California, San Francisco Medical Center (UCSF) has acquired a BSD-500 Hyperthermia System (BSD-500). UCSF is a world leader in hyperthermia and...
41 - Computable Genomix Announces Contest For Genomics Researchers
MEMPHIS, Tenn.-(Business Wire)-September 29, 2009 - Memphis-based Computable Genomix today announced it will launch a contest on Oct. 1, 2009, to coincide with the release of GeneIndexer, the company’s next-generation Web-based text-mining tool. Publish or Perish will award a $10,000 grant to each...
42 - Vivakor Announces Former General Electric Healthcare Division Executive Joins Its Board of Directors
CORALVILLE, Iowa-(Business Wire)-September 29, 2009 - Vivakor, Inc. (OTCBB: VIVK) today announced that John Gryga, former executive with General Electric’s Healthcare division and former Director of Operations for RadNet, has joined Vivakor’s Board of Directors. At RadNet, Mr. Gryga was...
43 - SAIC-Frederick and Roche Enter into a Research Collaboration on Technology Advancements for Cancer Gene Sequencing
MADISON, Wis.-(Business Wire)-September 29, 2009 - National Cancer Institute contractor SAIC-Frederick, Inc., a wholly owned subsidiary of Science Applications International Corporation (NYSE: SAI), and Roche Applied Science, a division of Roche Diagnostics Corporation (SWX:RO) (SWX:ROG) (Pink...
44 - Synta Pharmaceuticals Initiates Fourth Trial of STA-9090, a Novel Synthetic Small Molecule Hsp90 Inhibitor
LEXINGTON, Mass.-(Business Wire)-September 29, 2009 - Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it has initiated a Phase 1/2 clinical...
45 - Aurora Breast MRI of Sarasota and Clear Channel Radio, Partner for “Change for Change” Fundraising Event
SARASOTA, Fla.-(Business Wire)-September 29, 2009 - Aurora Breast MRI of Sarasota today announced it has partnered with Clear Channel Radio for a fundraising effort to benefit The Wellness Community of Southwest Florida. The fundraiser, titled “Change for Change,” will consist of a series of...
46 - Scarab Genomics Introduces ScarabXpress™ T7lac, a unique E. coli expression strain
MADISON, Wis.-(Business Wire)-September 29, 2009 - ScarabXpress is the latest strain in the multiple-deletion series (MDS) of Scarab Genomics Clean Genome® E. coli. Based on the MDS™42 strain, ScarabXpress T7lac contains a chromosomal copy of the T7 RNA polymerase gene expressed from a unique...
47 - Dynavax Initiates Phase 3 Registration Trial in Chronic Kidney Disease Patients for HEPLISAVTM Hepatitis B Vaccine
BERKELEY, Calif.-(Business Wire)-September 29, 2009 - Dynavax Technologies Corporation (Nasdaq:DVAX) today announced the initiation of a Phase 3 registration trial for HEPLISAVTM hepatitis B vaccine in individuals with chronic kidney disease. A second registration trial, a Phase 3 lot-to-lot...
48 - Repros Therapeutics Inc. Provides Update on Proellex
THE WOODLANDS, Texas-(Business Wire)-September 29, 2009 - Repros Therapeutics (NasdaqGM:RPRX) today announced that the Company has received further clarification from the Food and Drug Administration (FDA) on the Full Clinical Hold status of Proellex. As announced in early August 2009, and after...
49 - PPD Announces Third Quarter 2009 Earnings Release, Webcast and Conference Call
WILMINGTON, N.C.-(Business Wire)-September 29, 2009 - PPD, Inc. (Nasdaq: PPDI) will release its third quarter 2009 financial results on Tuesday, October 27, 2009, after the market closes. The earnings release will be available on the PPD Web site at http://www.ppdi.com, FirstCall and Business...
50 - BioClinica™ Showcases Clinical Data Management at SCDM Annual Conference
NEWTOWN, Pa.-(Business Wire)-September 29, 2009 - BioClinica, Inc., (NASDAQ: BIOC) a leading global provider of clinical trial services, is helping to advance the discipline of clinical data management and will demonstrate integrated eClinical and imaging data management technology and expertise...
51 - Precision BioSciences Announces U.S. Patent Office Reexamination of Cellectis Patents Involved in Litigation
RESEARCH TRIANGLE PARK, N.C.-(Business Wire)-September 29, 2009 - Precision BioSciences, Inc. today announced that the United States Patent and Trademark Office (PTO) has granted Precision’s requests for inter partes reexamination of U.S. Patent Nos. 6,610,545 (the ‘545 patent) and 7,309,605...
52 - Elan Corporation plc Announces Intent to Offer US$600M in Aggregate Principal Amount of Senior Fixed Rate Notes Due 2016
DUBLIN-(Business Wire)-September 29, 2009 - Elan Corporation, plc ("Elan") today announced that its wholly-owned subsidiaries, Elan Finance public limited company and Elan Finance Corp., intend to offer, subject to market conditions, US$600 million in aggregate principal amount of senior fixed...
53 - Elan Corporation Plc Announces Cash Tender for Outstanding US$850M in Aggregate Principal Amount of 2011 Fixed Rate Notes
DUBLIN, Ireland-(Business Wire)-September 29, 2009 - Elan Corporation, plc ("Elan") today announced that its wholly-owned subsidiaries, Elan Finance public limited company and Elan Finance Corp., are commencing a cash tender offer (the “Tender Offer”) for the outstanding US$850 million in...
54 - Inc. Magazine Names InVivo Therapeutics CEO Frank Reynolds one of ‘America’s Most Innovative Entrepreneurs’
CAMBRIDGE, Mass.-(Business Wire)-September 28, 2009 - Frank Reynolds, InVivo Therapeutics President and CEO, has been identified as one of ‘‘America’s most innovative entrepreneurs’ in the October 2009 issue of Inc. Magazine. In the article entitled “The New and Improved You,” Inc...
55 - Flexible Stenting Solutions, Inc. Receives Conditional IDE Approval for FlexStent® Femoropopliteal Self Expanding Stent System
EATONTOWN, N.J.-(Business Wire)-September 28, 2009 - Flexible Stenting Solutions Inc. (“FSS”), a leading developer of next generation peripheral arterial and biliary stents, announced today that it has received Conditional Investigational Device Exemption (IDE) approval for its FlexStent...
56 - Astrotech Reports Financial Results for Fourth Quarter and Fiscal Year 2009 and Announces Exploration of Strategic Alternatives
AUSTIN, Texas-(Business Wire)-September 28, 2009 - Astrotech Corporation (NASDAQ:ASTC) today announced financial results for its fourth quarter and fiscal year ended June 30, 2009. “This reporting period commemorates our return to profitable earnings and the completion of the turnaround for...
57 - Maxygen Announces Management Changes
REDWOOD CITY, Calif.-(Business Wire)-September 28, 2009 - Maxygen, Inc. (Nasdaq:MAXY) announced today that James Sulat, who currently serves as a director of the company, has been appointed to serve as Maxygen’s Chief Executive Officer, effective October 1, 2009. Mr. Sulat will replace Russell...
58 - Burzynski Research Institute Signs Research Agreement with the University of Alabama at Birmingham (UAB), Division of Preventive Medicine, Biostatistics and Bioinformatics Shared Facility
HOUSTON-(Business Wire)-September 28, 2009 - The Burzynski Research Institute, Inc. (BRI) today announced that it has signed a Research Agreement with the UAB Division of Preventive Medicine, Biostatistics and Bioinformatics Shared Facility (BBSF) that will provide biostatistical and data management...
59 - Impax Laboratories to Present at the JMP Securities Healthcare Focus Conference
HAYWARD, Calif.-(Business Wire)-September 28, 2009 - Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the JMP Securities Healthcare Focus Conference on Monday, October 5th, at 12:30 p.m. Eastern time. The conference will be held at The New York Palace Hotel...
60 - The Tennessee Biotechnology Association (TBA) Announces New Board Members
NASHVILLE, Tenn.-(Business Wire)-September 28, 2009 - The Tennessee Biotechnology Association: Richard Magid, PhD is Vice President at the University of Tennessee Research Foundation (UTRF) at the UT Health Science Center (UTHSC), and manages the operations of the Memphis office. This office is...
61 - Top Bioscience Industry Leaders H. Tom Watkins and Tony Zook to Address Mid-Atlantic Bio Conference
WASHINGTON-(Business Wire)-September 28, 2009 - H. Tom Watkins, president, CEO and director of Human Genome Sciences, Inc. (HGS) and Chair of The Maryland Life Sciences Advisory Board, and Tony Zook, AstraZeneca’s North America CEO and MedImmune’s President, will address the 2009 Mid-Atlantic...
62 - Medtronic Continues Membership in the Dow Jones Sustainability Index and FTSE4Good Index
MINNEAPOLIS-(Business Wire)-September 28, 2009 - Recognizing its leadership in meeting the needs of economic, environmental, and social stakeholders, Medtronic, Inc. (NYSE: MDT) has been named a member company in the Dow Jones Sustainability Index (DJSI) for North America and the FTSE4Good Index...
63 - Catalent Pharma Solutions Appoints New Sterile Segment President, Sales and Marketing Head
SOMERSET, N.J.-(Business Wire)-September 28, 2009 - Catalent Pharma Solutions, Inc. announced today the appointment of Will Downie in a dual role as Group President, Sterile Technologies and Senior Vice President of Global Sales & Marketing, effective October 12, 2009. Mr. Downie will have...
64 - Salix Pharmaceuticals to Present at JMP Securities Conference
RALEIGH, N.C.-(Business Wire)-September 28, 2009 - Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at the Fourth Annual JMP Securities Healthcare Focus Conference in New York, NY on Monday, October 5 at 11:30 a.m. ET. Interested parties can access a live audio...
65 - DiscoveryBioMed, Inc. Awarded Phase 2 SBIR Grant by the NIH to Discover Hypertension and Cystic Fibrosis (CF) Drugs
BIRMINGHAM, Ala.-(Business Wire)-September 28, 2009 - DiscoveryBioMed, Inc. (DBM) today announced that it has been awarded a $750,000 Small Business Innovations Research (SBIR) Phase 2 grant by the National Institutes of Health (NIH) to continue the research into the discovery and development of...
66 - Savvion and Patni Announce Strategic Partnership
SANTA CLARA, Calif.-(Business Wire)-September 28, 2009 - Savvion® and Patni Life Sciences announced today a strategic partnership to jointly deliver Business Process Management (BPM)-enabled solutions for clinical operations on top of Savvion’s Life Sciences Foundation. Savvion and Patni will...
67 - German Consulate & State of Hessen Life Science Networking Event: “Innovative Solutions to Challenges in Life Science in Germany,” New York, Tuesday 10/6/2009
NEW YORK-(Business Wire)-September 28, 2009 - German State of Hessen U.S. Office for Economic Development: German Life Science Speaker Panel and Networking Reception Welcome & Introduction: Dr. Horst Freitag, Consul General Speakers: Dr. Christian Garbe, Managing Director FIZ Frankfurt...
68 - Biomagnetics Diagnostics Receives a Financing Commitment up to $1 Million to Speed Development of Malaria Testing Technology
GENEVA-(Business Wire)-September 28, 2009 - Biomagnetics Diagnostics Corp., (PINK SHEETS:BMGP) a producer of revolutionary diagnostic systems and technology for malaria, tuberculosis, HIV and hepatitis testing today announced it has received a equity-based financing commitment up to $1 million...
69 - BioForward Announces Moderator, Panelists for Summit’s Final Plenary Session
MADISON, Wis.-(Business Wire)-September 28, 2009 - BioForward, the member-driven state association that is the voice of Wisconsin’s biotechnology industry, today announced moderator and panel participants for the closing plenary of the Biotechnology Vision Summit. The organization’s new...
70 - iCAD to Present at America’s Growth Capital 6th Annual East Coast Emerging Growth Conference
NASHUA, N.H.-(Business Wire)-September 28, 2009 - iCAD, Inc. (NASDAQ: ICAD), an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, today announced that Ken Ferry, President and Chief Executive Officer and Darlene Deptula-Hicks...
71 - Ligand and GlaxoSmithKline Collaboration Identifies New Compound
SAN DIEGO-(Business Wire)-September 28, 2009 - Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that pursuant to an amendment to a March 2006 research agreement with GlaxoSmithKline (NYSE:GSK), GSK has agreed to accelerate the timing of a $500,000 payment to Ligand that would...
72 - Leading Japanese CRO Attains Highest Accreditation in Medidata Solutions’ ASPire to Win Partner Program
NEW YORK & TOKYO-(Business Wire)-September 28, 2009 - Medidata Solutions (NASDAQ: MDSO), a leading global provider of hosted clinical development solutions, today announced that CMIC, one of the largest contract research organizations (CROs) in Japan, has attained Rave Accredited Plus, the...
73 - Celsion Corporation Announces $7.1 Million Registered Direct Offering
COLUMBIA, Md.-(Business Wire)-September 28, 2009 - Celsion Corporation (the “Company”) (NASDAQ: CLSN), an innovative oncology drug development company dedicated to the development and commercialization of innovative oncology drugs, today announced that it has entered into definitive agreements...
74 - Lifeline Biotechnologies Completes the Updating of Pink Sheets
RENO, Nev.-(Business Wire)-September 28, 2009 - Lifeline Biotechnologies, Inc. (Pink Sheets:LLBO) today announced that it has completed the updating of the Company’s information on Pinks Sheets. Jim Holmes, Lifeline’s CEO, said, “The ‘Stop Sign’ on our Company site at Pink Sheets has...
75 - PolyMedix Receives U.S. Patent Protection for Licensed Computational Methods to Design Antimicrobial Polymers
RADNOR, Pa.-(Business Wire)-September 28, 2009 - PolyMedix, Inc. (OTC BB: PYMX, http://polymedix.com), an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has received patent protection for...
76 - RXi Pharmaceuticals to Webcast Investor Event on October 5, 2009
WORCESTER, Mass.-(Business Wire)-September 28, 2009 - RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that it will webcast its Second Annual...
77 - Pappas Ventures Names Eric Linsley Managing Partner
RESEARCH TRIANGLE PARK, N.C.-(Business Wire)-September 28, 2009 - Pappas Ventures today announced that Eric W. Linsley has been promoted to Managing Partner. As managing partner, Linsley will play an enhanced leadership role on a team of investment, biotechnology and medical professionals who manage...
78 - TRADE NEWS: Agilent Technologies Introduces New Complex Proteomics Standard at HUPO 8th Annual World Congress
TORONTO-(Business Wire)-September 28, 2009 - Agilent Technologies Inc. (NYSE:A) today announced the new Agilent Complex Proteomics Standard, created to help researchers with protein biomarker discovery by validating mass-spectrometry-based workflows for protein identification. It is the most...
79 - PerkinElmer’s Exclusive Hyphenated Scientific Instrumentation Allows Simultaneous Testing for the Drug and Plastic Industries
SHELTON, Conn.-(Business Wire)-September 28, 2009 - PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, has emerged as a leader in hyphenated scientific instrumentation with the launch of its exclusive Differential Scanning Calorimetry (DSC)-Raman...
80 - CSL Biotherapies Reaches Agreement with Merck & Co. on Rights to Market and Distribute Afluria® in the U.S.
KING OF PRUSSIA, Pa.-(Business Wire)-September 28, 2009 - CSL Biotherapies and its parent company, CSL Limited (ASX:CSL), one of the world's leading manufacturers of influenza vaccine, have reached an agreement with Merck & Co., Inc. on rights to market and distribute Afluria® in the United...
81 - Helicos Announces System Sale to Correlagen Diagnostics
CAMBRIDGE, Mass.-(Business Wire)-September 28, 2009 - Helicos BioSciences Corporation (NASDAQ: HLCS) today announced the sale of a system and a scientific collaboration with Correlagen Diagnostics Inc., a leading provider of genetic tests for disease diagnosis. “We are very excited to have...
82 - Halozyme Begins Clinical Trial to Compare Three Insulin Analogs and Provides Update on Ultrafast Insulin Program
SAN DIEGO-(Business Wire)-September 28, 2009 - Halozyme Therapeutics, Inc. (Nasdaq:HALO) today announced the commencement of a Phase 1 clinical study that will assess the effects of three approved prandial (mealtime) insulin analogs administered with its proprietary rHuPH20 (PH20) hyaluronidase...
83 - Selcia Launches New Discovery Division with Powerful Fragment Screening Platform and Unveil Company Re-brand
ONGAR, Essex, UK-(Business Wire)-September 28, 2009 - Selcia Ltd, a worldwide industry leading C-14 custom radiolabelling provider and drug discovery company this week launched their new Fragment Screening Platform and unveiled their new brand as part of ambitious international expansion plans...
84 - Correlagen Announces Acquisition of System from Helicos BioSciences
WALTHAM, Mass.-(Business Wire)-September 28, 2009 - Correlagen Diagnostics Inc., a leading provider of genetic testing for disease diagnosis, today announced the acquisition of a system from and a scientific collaboration with Helicos BioSciences Corporation (NASDAQ: HLCS). “We believe that the...
85 - Life Technologies and febit Team to Offer New Solution for Targeted Re-sequencing in Large-scale Genomic Studies
CARLSBAD, Calif. & HEIDELBERG, Germany-(Business Wire)-September 28, 2009 - febit holding GmbH and Life Technologies Corporation (NASDAQ: LIFE) today announced that they have entered into a strategic co-marketing agreement to provide a new, scalable solution for researchers conducting targeted...
86 - Covidien Announces Definitive Agreement to Acquire Aspect Medical Systems, Inc.
DUBLIN, Ireland & NORWOOD, Mass.-(Business Wire)-September 28, 2009 - Covidien (NYSE: COV) and Aspect Medical Systems, Inc. (NASDAQ: ASPM) today announced that Covidien has reached a definitive agreement to acquire Aspect, a global market leader in brain monitoring technology. The Boards of...
87 - Inovio Biomedical to Present at Vaccine 3rd Global Congress
SAN DIEGO-(Business Wire)-September 28, 2009 - Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced today it will make multiple presentations at the Vaccine 3rd Global Congress being held in Singapore October 4th – 6th. Inovio...
88 - Vitrolife: Swemed Sense™ approved for sales in Australia
STOCKHOLM, Sweden-(Business Wire)-September 28, 2009 - Regulatory News: “Swemed Sense™, with its unique characteristics, is an important part of our existing product portfolio in Europe, and is now available even to our Australian customers, Says Vitrolife's Vice President of Marketing and...
89 - Merck Receives Positive CHMP Opinion for JANUVIA® (sitagliptin) and JANUMET® (sitagliptin/metformin) as Add-On to Insulin in the European Union
WHITEHOUSE STATION, N.J.-(Business Wire)-September 25, 2009 - Merck & Co., Inc., which operates in many countries as Merck Sharp & Dohme (MSD), has received a positive opinion from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) for JANUVIA...
90 - Initial Clinical Results for New Omnisure™ Sling Released at the AUGS Annual Meeting
RAYNHAM, Mass.-(Business Wire)-September 25, 2009 - Mpathy Medical, a rapidly growing medical device company which has developed and brought to market a range of less invasive surgical solutions used to restore pelvic health to women, released the initial clinical results for its newest product...
91 - Accelr8 and Becton Dickinson Conclude Technical Development Project
DENVER-(Business Wire)-September 25, 2009 - Accelr8 Technology Corporation (NYSE Amex: AXK) announced today that it has concluded a technical development project with Becton, Dickinson and Company (“BD”) (NYSE: BDX). Accelr8’s technology met formal testing requirements for identification of...
92 - Research and Markets: Top 10 Companies in the US Life Sciences Industry: IT Spending Predictor 2009 Out Now
DUBLIN-(Business Wire)-September 25, 2009 - Research and Markets has announced the addition of the "Top 10 Companies in the US Life Sciences Industry: IT Spending Predictor 2009" report to their offering. This databook provides insight into the top 10 companies in the US life sciences industry in...
93 - Research and Markets: Opportunities For Biosimilars Market Is Immense, As Biologics Worth US$25 Billion Are Going To Be Off-Patent By 2016
DUBLIN-(Business Wire)-September 25, 2009 - Research and Markets Ltd. Biopartners Cangene Cinnagen Inc. Claris Lifesciences Dong-A Pharmaceutical Dr. Reddy'S Laboratories Dsm Biologics Dynavax Technologies Emcure Genescience Pharmaceuticals Co Ltd. Gtc Biotherapeutics Ltd. Hospira Inc. Intas...
94 - Affymax Secures $60 Million Issuer Managed Equity Facility with Azimuth Opportunity, Ltd.
PALO ALTO, Calif.-(Business Wire)-September 25, 2009 - Affymax, Inc. (Nasdaq:AFFY) today announced that it has obtained an issuer managed equity facility under which it may sell up to $60 million of its registered common stock to Azimuth Opportunity, Ltd. Affymax is not obligated to utilize any of...
95 - Quintiles and Allergan Announce Co-Promotion for Sanctura XR®
RESEARCH TRIANGLE PARK, N.C.-(Business Wire)-September 25, 2009 - Quintiles Transnational Corp. and Allergan, Inc. (NYSE: AGN) today announced an agreement under which Quintiles will co-promote Allergan's SANCTURA XR® (trospium chloride extended release capsules), an anticholinergic approved for...
96 - Covidien Announces Dividend Increase of 12.5%
DUBLIN-(Business Wire)-September 25, 2009 - Covidien plc (NYSE: COV) today announced that its Board of Directors has declared a 12.5% increase in the quarterly dividend rate, from $0.16 per ordinary share to $0.18 per ordinary share. “Given our good operational performance thus far in 2009, our...
97 - Idera Pharmaceuticals Presents Final Data from Phase 2 Clinical Trial of IMO-2055 Monotherapy in Renal Cell Carcinoma
CAMBRIDGE, Mass.-(Business Wire)-September 25, 2009 - Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced the presentation of final data from a clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, as monotherapy in patients with Renal Cell Carcinoma (RCC). The data...
98 - Advaxis Secures $5.0 Million Investment
NORTH BRUNSWICK, N.J.-(Business Wire)-September 25, 2009 - Advaxis, Inc. (OTCBB: ADXS), has entered into a definitive agreement for a $5 million investment commitment (the “Investment”) with an investment fund (the “Investor”). “This financing, combined with our current debt offering, will...
99 - RXi Pharmaceuticals Obtains Direct Ownership of Previously Licensed RNAi Delivery Intellectual Property
WORCESTER, Mass.-(Business Wire)-September 25, 2009 - RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that it has recently acquired direct...
100 - EnzymeRx Announces Its IND for Uricase-PEG 20 Becomes Effective
PARAMUS, N.J.-(Business Wire)-September 25, 2009 - EnzymeRx, LLC (www.enzymerx.com), a clinical-stage biotechnology company, today announced that its Investigational New Drug (IND) application for Uricase-PEG 20, filed with the U.S. Food and Drug Administration (FDA) last month, has become...
101 - Altor BioScience Awarded $3 MM SBIR Bridge Grant by NCI to Advance Clinical Trials for its Targeted Cancer Therapeutic ALT-801
MIRAMAR, Fla.-(Business Wire)-September 25, 2009 - Altor BioScience Corporation announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase II Bridge Grant by the National Cancer Institute (NCI). The award of $3 MM over three years will help Altor further its...
102 - Dyax Corp. to Present at the JMP Securities Healthcare Focus Conference
CAMBRIDGE, Mass.-(Business Wire)-September 25, 2009 - Dyax Corp. (NASDAQ:DYAX), a developer of novel biotherapeutics for unmet medical needs, announced today that Gustav A. Christensen, President and Chief Executive Officer of Dyax, will present at the Fourth Annual JMP Securities Healthcare Focus...
103 - NCKU Aquatic Animal Bio-Medicine R&D Team Awarded Gold Medal and Bronze Medal Again
TAINAN, Taiwan-(Business Wire)-September 25, 2009 - The Aquatic Animal Bio-Medicine R&D Team (AABM Team) of National Cheng Kung University (NCKU) in Taiwan, led by Distinguished Prof. Huey-Lang Yang from Institute of Biotechnology, won two medals out of more than 100 teams in the national...
104 - Allos Therapeutics’ FOLOTYN™ First and Only FDA-Approved Therapy for Relapsed or Refractory Peripheral T-cell Lymphoma
WESTMINSTER, Colo.-(Business Wire)-September 25, 2009 - Allos Therapeutics, Inc. (Nasdaq:ALTH) today announced that last night the U.S. Food and Drug Administration (FDA) granted accelerated approval for FOLOTYNTM (pralatrexate injection) for use as a single agent for the treatment of patients...
105 - Research and Markets: Modern Biotechnology: Connecting Innovations in Microbiology and Biochemistry to Engineering Fundamentals - Now Available
DUBLIN-(Business Wire)-September 25, 2009 - Research and Markets has announced the addition of John Wiley and Sons Ltd's new report "Modern Biotechnology : Connecting Innovations in Microbiology and Biochemistry to Engineering Fundamentals" to their offering. A unique resource for the next...
106 - Pfizer and Eisai Continue Aricept Collaboration
NEW YORK-(Business Wire)-September 25, 2009 - Pfizer Inc (NYSE: PFE) today announced that its agreement with Eisai to provide Aricept to patients suffering from Alzheimer’s disease will continue without interruption. Under this redefined alliance, which resolves a previously disclosed dispute...
107 - Incyte Prices $350 Million Convertible Senior Notes Offering
WILMINGTON, Del.-(Business Wire)-September 24, 2009 - Incyte Corporation (Nasdaq: INCY) today announced the pricing of its offering of $350 million aggregate principal amount of 4.75% Convertible Senior Notes due 2015 in a private placement to qualified institutional buyers pursuant to exemptions...
108 - Incyte Announces Pricing of Public Offering of 18,000,000 Shares of Common Stock
WILMINGTON, Del.-(Business Wire)-September 24, 2009 - Incyte Corporation (Nasdaq:INCY) today announced the pricing of its underwritten public offering of 18,000,000 shares of its common stock at a price to the public of $6.75 per share. The offering is expected to close on September 30, 2009...
109 - AED Plus Save of 16-Year-Old Football Player in Minnesota Underscores the Importance of Having AEDs in Schools and at Sports Events
CHELMSFORD, Mass.-(Business Wire)-September 24, 2009 - ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of resuscitation devices and related software solutions, and the Sudden Cardiac Arrest Foundation today are jointly issuing a reminder in conjunction with SCA Awareness Month in...
110 - Tryton Medical, Inc. Broadcasts Successful Live Case Using Company’s Side-Branch Stent™ to Definitively Treat Bifurcation Lesions at TCT 2009
DURHAM, N.C. & SAN FRANCISCO-(Business Wire)-September 24, 2009 - Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, announced today the transmission of a live satellite feed of a clinical case performed in the United Kingdom to an...
111 - Chromatin, Inc. Adds Two to Executive Team
CHICAGO-(Business Wire)-September 24, 2009 - Chromatin, Inc. announced today two additions to its executive team. Ken Davenport will serve as the Vice President of Strategic Development and Jeff Scheib will serve as the Vice President of Biofuels. Ken Davenport has over 27 years of chemical...
112 - Advaxis Cures Late Form 10-Q Filing
NORTH BRUNSWICK, N.J.-(Business Wire)-September 24, 2009 - Advaxis, Inc. (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, announced today that the Company's ticker symbol has been temporarily changed to ADXSE denoting untimely filing of the Company’s July 31, 2009...
113 - GeneWize Life Sciences, Inc., Approved As New Member of Direct Selling Association
ORLANDO, Fla.-(Business Wire)-September 24, 2009 - GeneWize Life Sciences, Inc. (“GeneWize”), subsidiary of leading consumer genomics biotech company GeneLink, Inc. (OTCBB: GNLK.OB, “GeneLink”), today announced that the Direct Selling Association (“DSA”) has approved its application...
114 - Vertex Pharmaceuticals Announces Publication of Telaprevir Abstracts for Presentation at the 60th AASLD Meeting
CAMBRIDGE, Mass.-(Business Wire)-September 24, 2009 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that sustained virologic response (SVR) data from Study C208, which evaluated twice-daily dosing of Vertex’s investigational hepatitis C virus (HCV) protease inhibitor...
115 - HRC Fertility Offers Gene Security Parental Control for Embryonic Safety
PASADENA, Calif.-(Business Wire)-September 24, 2009 - Over the past twenty-one years, HRC Fertility has focused on introducing and perfecting new procedures and techniques that are on the cutting edge of reproductive technology. Together with the American Society for Reproductive Medicine (ASRM...
116 - Imprime PGG® Named a Top 10 Oncology Drug Candidate for Partnering
EAGAN, Minn.-(Business Wire)-September 24, 2009 - Biothera, a privately held biotechnology company, announced today that its lead drug candidate, Imprime PGG®, has been named one of the Top 10 Most Interesting Oncology Projects Available for Partnering by Windhover Information Inc. in conjunction...
117 - Inhibitex Regains Compliance with NASDAQ Listing Requirements
ATLANTA-(Business Wire)-September 24, 2009 - Inhibitex, Inc. (Nasdaq: INHX) (the “Company”), a biopharmaceutical company focused on developing products to treat serious infectious diseases, announced today that it has received notice from The NASDAQ Stock Market ("Nasdaq") stating that, as the...
118 - ProtoKinetix’ Advisory Boards Launch Major Commercial Initiatives for It’s AAGPs™
VANCOUVER-(Business Wire)-September 24, 2009 - ProtoKinetix’ Business Advisory Board Chairman, Rear Admiral (Ret) Dr. Edward Martin, reported on progress implemented by the Corporate Advisory Boards. Attending the recent conference were Major General (Ret) Dr. John Parker and Vice Admiral (Ret...
119 - TRADE NEWS: Agilent Technologies, Shanghai Institute of Biological Sciences and Chinese Academy of Sciences Open Center for Systems Biology
SANTA CLARA, Calif. & SHANGHAI-(Business Wire)-September 24, 2009 - Agilent Technologies Inc. (NYSE:A) today announced the opening of the Shanghai Institute of Biological Sciences (SIBS)-Agilent Center for Systems Biology in Shanghai, China. The center will feature multiple technology...
120 - Boston Scientific Founder John Abele Joins Nanobiosym Global Advisory Board
BOSTON-(Business Wire)-September 24, 2009 - Nanobiosym® today announced that John Abele, Cofounder and former Co-Chairman of the multibillion-dollar global medical device company, Boston Scientific, has joined the Nanobiosym Global Advisory Board. Over the past 30 years, Mr. Abele led the...
121 - AmazingCharts.com Named Fastest-Growing Company In Rhode Island by Prestigious 2009 Inc. 500/5000 List
SAUNDERSTOWN, R.I.-(Business Wire)-September 24, 2009 - AmazingCharts.com, Inc., a leading developer of Electronic Medical Record (EMR) systems was named the fastest growing private company in Rhode Island by Inc. Magazine's list of the "5000 Fastest Growing Private Companies in America." With...
122 - RegeneRx Biopharmaceuticals to Present Several Papers at Second International Symposium on Thymosins in Health and Disease
BETHESDA, Md.-(Business Wire)-September 24, 2009 - REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) (www.regenerx.com) announced today that it will participate in the Second International Symposium on Thymosins in Health and Disease. This conference will take place from September 30, through...
123 - Catalent and GlaxoSmithKline Extend Contractual Agreement
SOMERSET, N.J.-(Business Wire)-September 24, 2009 - Catalent Pharma Solutions and GlaxoSmithKline (GSK) have agreed to extend their contractual relationship where Catalent will continue to supply GSK with its trade requirements of Lovaza® omega-3 acid ethyl esters in soft gelatin capsules. Lovaza...
124 - MEDICREA PASS® LP De-Rotation Connector on the U.S. Market
LYON, France-(Business Wire)-September 24, 2009 - MEDICREA® (Paris:ALMED) announced today the launch of the PASS® LP De-Rotation connector on the U.S. market, and the preparation of a U.S. prospective multicenter clinical study analyzing the 3D correction of adolescent idiopathic scoliosis by...
125 - IMS Health Launches ‘Ask IMS’ to Help Early-Stage Biopharmaceutical Companies Enhance Business Development, Commercialization Strategies
NORWALK, Conn.-(Business Wire)-September 24, 2009 - IMS Health (NYSE: RX) today announced the launch of Ask IMSTM, a cost-effective, Web-based service that provides strategic market intelligence to help drive the growth and success of early-stage biopharmaceutical companies. Drawn from IMS’s...
126 - Advanced BioHealing Showcases Dermagraft at Georgetown University’s Diabetic Limb Salvage Conference
WASHINGTON-(Business Wire)-September 24, 2009 - Advanced BioHealing, Inc. (ABH), a leader in commercializing the promise of regenerative medicine, today announced that Dermagraft®, its bio-engineered skin substitute that repairs tissue damaged by disease or injury and supports the body’s...
127 - Integrated Environmental Technologies, Ltd. Announces EcaFlo® Anolyte (Excelyte®) Effective Against Swine Flu (H1N1)
LITTLE RIVER, S.C.-(Business Wire)-September 24, 2009 - Integrated Environmental Technologies, Ltd. (OTCBB: IEVM) announces the successful results of IET’s EcaFlo® Anolyte solution, marketed as Excelyte®, against Swine Influenza (H1N1). Specific testing performed by Microbiotest Labs of...
128 - Health Discovery Corporation’s Dr. Stephen Barnhill Tells Participants at London Conference That Biomarkers Patented by His Company Promise to Revolutionize The Field of Molecular Diagnostics
SAVANNAH, Ga.-(Business Wire)-September 24, 2009 - Dr. Stephen Barnhill, Chairman and CEO, Health Discovery Corporation (OTCBB: HDVY) (“HDC”), a molecular diagnostics company, spoke at the “Biomarkers in Clinical Trials” Conference taking place in London, September 23-24, 2009. The...
129 - PHT Corporation Promotes Dwight Cooper to Vice President of Client Services
BOSTON-(Business Wire)-September 24, 2009 - PHT Corporation, the leading provider of ePRO solutions used in pharmaceutical and biotechnology clinical trials worldwide, today announced the promotion of company executive Dwight Cooper to Vice President of Client Services. Mr. Cooper has over 15...
130 - Prime-Boost Vaccine Study Shows Modest Effect in Preventing HIV
SOUTH SAN FRANCISCO, Calif.-(Business Wire)-September 24, 2009 - Global Solutions for Infectious Diseases (“GSID”) announced today that a Phase III clinical trial of an investigational HIV vaccine regimen has been shown to be safe and modestly effective in preventing HIV infection. The...
131 - The Wall Street Transcript Interviews Nutra Pharma Chairman and CEO
PLANTATION, Fla.-(Business Wire)-September 24, 2009 - Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its Chairman and CEO, Rik J Deitsch, has been interviewed for the...
132 - Inovio Biomedical CEO Addresses MIT’s Emerging Technologies Conference
SAN DIEGO-(Business Wire)-September 24, 2009 - Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced today that Dr. J. Joseph Kim, Inovio’s CEO, presented keynote remarks at MIT’s Emerging Technologies Conference hosted by the...
133 - Genzyme’s Campath Meets Primary Endpoint in Phase 3 Combination Therapy Trial for Chronic Lymphocytic Leukemia
CAMBRIDGE, Mass.-(Business Wire)-September 24, 2009 - Genzyme Corporation (Nasdaq: GENZ) announced today that its randomized Phase 3 clinical trial investigating Campath® (alemtuzumab) in combination with Fludara® (fludarabine phosphate) in relapsed or refractory chronic lymphocytic leukemia (CLL...
134 - IsoRay Inc. Announces Fiscal Year 2009 Results
RICHLAND, Wash.-(Business Wire)-September 24, 2009 - IsoRay Inc. (AMEX:ISR), a medical isotope company focused on the treatment of lung cancer, head and neck tumors, prostate cancer and other malignant disease through use of its proprietary radioisotope technology, announces today its financial...
135 - Liquidia Founder Receives Prestigious NIH Director’s Pioneer Award
RESEARCH TRIANGLE PARK, N.C.-(Business Wire)-September 24, 2009 - Liquidia Technologies today announced its founder, Dr. Joseph DeSimone, has received the National Institutes of Health (NIH) Director’s Pioneer Award. Pioneer Awards are designed to support individual scientists of exceptional...
136 - 17th Annual BioPartnering Europe™ and BioPartnering China™ Presents Innovative and Informative Program, Addressing Latest Trends Affecting the Biotech Industry Today
LONDON-(Business Wire)-September 24, 2009 - Technology Vision Group (TVG) is pleased to announce details of the program for the 17th Annual BioPartnering Europe (BPE) and BioPartnering China (BPC) conference in London from 11-14 October 2009, providing four days of networking in one location...
137 - Alkermes Announces Amylin and Lilly Will Present More than 20 Studies for Exenatide at EASD 2009
SAN DIEGO & INDIANAPOLIS & CAMBRIDGE, Mass.-(Business Wire)-September 24, 2009 - Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) will unveil data from more than 20 studies at the 45th Annual Meeting of the European...
138 - BSD Medical Corporation Files $50 Million Shelf Registration
SALT LAKE CITY-(Business Wire)-September 24, 2009 - BSD Medical Corporation (NASDAQ:BSDM) (www.BSDMedical.com) today announced the filing of a shelf registration statement on Form S-3 with the Securities and Exchange Commission. The shelf registration statement, when declared effective by the...
139 - Global Prostate Cancer Research Meeting Opens
SANTA MONICA, Calif.-(Business Wire)-September 24, 2009 - Nearly of 300 of the world’s leading researchers focused on the problem of prostate cancer will begin a three-day meeting today to discuss the latest scientific data and breakthroughs in prostate cancer. The meeting, held in Incline Village...
140 - Helicos Announces First-Ever Direct Sequencing of Single Molecules of RNA
CAMBRIDGE, Mass.-(Business Wire)-September 24, 2009 - Helicos BioSciences Corporation (NASDAQ: HLCS), a life science company focused on innovative genetic analysis technologies, today announced the publication of a landmark study in which Helicos’ True Single Molecule Sequencing (tSMS...
141 - Nanoviricides, Inc. CEO Dr. Eugene Seymour to Address the Livingston Healthcare and Life Science Stakeholders Summit
WEST HAVEN, Conn.-(Business Wire)-September 24, 2009 - NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that the Company’s CEO, Eugene Seymour, MD, MPH has been invited as a panelist at the 2nd Annual Livingston Healthcare Summit on September 24th, 2009 in New York City...
142 - Pro-Pharmaceuticals to Present a Corporate Update at the Maxim Group Growth Conference
NEWTON, Mass.-(Business Wire)-September 24, 2009 - Pro-Pharmaceuticals, Inc. (OTC: PRWP) today announced that Theodore Zucconi, Ph.D., Chief Executive Officer, and James Czirr, Chairman of the Board, Pro-Pharmaceuticals, Inc., are scheduled to present a corporate update at the Maxim Group Growth...
143 - Sepracor Announces Expiration of Hart-Scott-Rodino Waiting Period
MARLBOROUGH, Mass.-(Business Wire)-September 24, 2009 - Sepracor Inc. ("Sepracor", NASDAQ: SEPR) today announces that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), applicable to the acquisition of Sepracor by Dainippon Sumitomo...
144 - Teva Provides Update on Generic Evista® Litigation
JERUSALEM-(Business Wire)-September 24, 2009 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. District Court for the Southern District of Indiana has issued a decision invalidating two patents listed in the FDA’s Orange Book for Eli Lilly’s Evista...
145 - Life Technologies Initiates Suit Against Illumina Alleging Patent Infringement
SAN DIEGO-(Business Wire)-September 24, 2009 - Illumina, Inc. (Nasdaq:ILMN) today announced that it has been served with a complaint filed on September 21, 2009 in the U.S. District Court in Wilmington, Delaware naming Illumina as a defendant. The complaint names as plaintiffs Life Technologies...
146 - Emergent Health Corp. (EMGE) Announces Pending Stock Split
KING OF PRUSSIA, Pa.-(Business Wire)-September 24, 2009 - Emergent Health Corp. (Other OTC: EMGE) Emergent expects to review a stock split to increase shares for each share currently owned by existing shareholders. The final decision for the actual split ratio is expected to be made by October 31...
147 - Results of ADAGIO Study with AZILECT® in Parkinson’s Disease Published in New England Journal of Medicine
JERUSALEM-(Business Wire)-September 23, 2009 - Results from the ADAGIO trial, published online today in The New England Journal of Medicine, demonstrated that Parkinson’s disease patients receiving AZILECT® (rasagiline) 1mg/day at the start of the study (early-start group) experienced superior...
148 - Cambridge Heart Announces New Research and Development Initiative
TEWKSBURY, Mass.-(Business Wire)-September 23, 2009 - Cambridge Heart, Inc. (OTCBB-CAMH) announced today that it intends to pursue research and development efforts on a new application derived from its core Microvolt T-Wave Alternans (MTWA) technology. The Company has gathered data, which although...
149 - FDA Advisory Committee Hears Presentations and Public Comment on EXALGO Extended-Release Tablets
CAMBRIDGE, Mass. & VANCOUVER-(Business Wire)-September 23, 2009 - CombinatoRx, Incorporated (NASDAQ: CRXX) and Neuromed Pharmaceuticals, Inc., a privately-held biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) in a joint meeting of its Anesthetics and...
150 - FDA Advisory Committee Hears Presentations and Public Comment on EXALGO Extended-Release Tablets
ST. LOUIS-(Business Wire)-September 23, 2009 - Covidien (NYSE:COV), a leading global provider of healthcare products, today announced that it presented information to members of a U.S. Food and Drug Administration (FDA) Advisory Committee on the New Drug Application and proposed Risk Evaluation...
151 - Purohit Navigation Engages Users in Its New Web Site
CHICAGO-(Business Wire)-September 23, 2009 - Not all healthcare agency Web sites are created equal, as Purohit Navigation’s redesigned Web site (purohitnavigation.com) demonstrates. To engage visitors to the Web site immediately, Purohit Navigation has strategically used animation and design to...
152 - PsoriasisDX and HairDX To Present “Pharmacogenomics In Dermatology And Cosmetics” During EADV Congress
BERLIN & IRVINE, Calif.-(Business Wire)-September 23, 2009 - A symposium about “Pharmacogenomics In Dermatology And Cosmetics” will be presented on Thursday, October 8 to coincide with the 18th European Academy of Dermatology and Venereology (EADV) Congress. It will be held at the...
153 - BioPharm America™ 2009 in San Francisco Sets New Benchmark for Partnering Productivity in the US
CARLSBAD, Calif. & SAN FRANCISCO-(Business Wire)-September 23, 2009 - Over 700 leaders from the biotechnology and pharmaceutical industry gathered last week for the 2nd annual BioPharm America™ partnering conference, which saw delegates from 665 companies engage in 1579 one-to-one partnering...
154 - RainDance Expands Sequence Enrichment Solution Capabilities with 20,000 Amplicon Library and Whole Genome Amplification Protocol
PROVIDENCE, R.I.-(Business Wire)-September 23, 2009 - RainDance Technologies, Inc., a leading provider of innovative microdroplet-based solutions for health and human disease research, announced today it has expanded the capabilities of its Sequence Enrichment Solution to enable the resequencing...
155 - Cook Medical’s Advanced NavAlign™ Delivery System for IVC Filters Adds Procedural Speed, Control and Accuracy
SAN FRANCISCO-(Business Wire)-September 23, 2009 - Physicians can now navigate even the most tortuous anatomy with greater speed and safety with the next-generation inferior vena cava (IVC) filter delivery system introduced today by Cook Medical at TCT 2009. The release of the NavAlign™ delivery...
156 - Perlegen Introduces BREVAGen™ Breast Cancer Risk Stratification Test
MOUNTAIN VIEW, Calif.-(Business Wire)-September 23, 2009 - Perlegen Sciences, which develops genetic tests that correlate genetic variation to disease risk and drug response, announced today that its BREVAGen™ breast cancer risk stratification test is now clinically available in select U.S...
157 - BioVectra Announces Oncolix Inc. Signs Manufacturing and Investment Agreement
CHARLOTTETOWN, PEI-(Business Wire)-September 23, 2009 - BioVectra, Inc., a cGMP manufacturing and development partner in Charlottetown, PEI, Canada, announces that it has reached an agreement with Oncolix Inc., a biopharmaceutical company based in Houston, Texas, to manufacture ProlantaTM for...
158 - Cook Incorporated Wins Patent Infringement Appeal Filed By Edwards Lifesciences
BLOOMINGTON, Ind.-(Business Wire)-September 23, 2009 - The United States Court of Appeals for the Federal Circuit today affirmed the previous ruling of the United States District Court for the Northern District of California that Cook Incorporated does not infringe on Edwards’ patents for...
159 - LifeSensors, Inc. Obtains Worldwide, Exclusive License to High Affinity “Ubiquitin Traps”
MALVERN, Pa.-(Business Wire)-September 23, 2009 - LifeSensors, Inc., a biotechnology company specializing in protein expression technologies and ubiquitin pathway research tools, announced today their worldwide, exclusive license for high affinity ubiquitin traps. These new research tools, developed...
160 - European Commission Grants Conditional Marketing Authorization to Cayston® (Aztreonam Lysine) for the Treatment of Chronic Pulmonary Infections Due to Pseudomonas Aeruginosa in Patients with Cystic Fibrosis
FOSTER CITY, Calif.-(Business Wire)-September 23, 2009 - Gilead Sciences, Inc. (Nasdaq:GILD) announced today that the European Commission has granted conditional marketing authorization for Cayston® 75 mg powder and solvent for nebuliser solution (aztreonam lysine) for the suppressive therapy of...
161 - Celladon's MYDICAR® and Small Molecule SERCA2a Studies in Acute and Chronic Heart Failure Selected as One of Windhover’s Top 10 Cardiovascular Programs to Watch
SAN DIEGO-(Business Wire)-September 23, 2009 - Celladon Corporation today announced that its SERCA2a programs for the treatment of patients with acute and chronic heart failure have been chosen by Windhover and an independent expert panel as one of the top 10 most interesting cardiovascular projects...
162 - ImThera Medical Completes Development of Targeted Hypoglossal Neurostimulation Treatment for OSA
SAN DIEGO-(Business Wire)-September 23, 2009 - ImThera Medical, Inc. announced today that it has completed development of its Targeted Hypoglossal Neurostimulation (THN) system for Obstructive Sleep Apnea (OSA). More than 800,000 patients in the US are annually diagnosed with OSA. While Continuous...
163 - Research and Markets: Biological Product (except Diagnostic) Manufacturing Industry in the U.S. and its International Trade [Q3 2009 Edition]
DUBLIN-(Business Wire)-September 23, 2009 - Research and Markets Manufacturing Industry report provides the latest market research on the industry. Its comprehensive scope contains analysis on the industrys key financial data, competitive landscape, upstream and downstream industries, and trends...
164 - MicroDose Therapeutx Announces Initiation of Phase 1 Study with Inhaled Atropine as Antidote to Combat Effects of Nerve Agent Poisoning
MONMOUTH JUNCTION, N.J.-(Business Wire)-September 23, 2009 - MicroDose Therapeutx Inc. (formerly MicroDose Technologies) today announced that it has initiated a Phase I study at the University of Pittsburgh Medical Center with atropine sulfate delivered from the MicroDose proprietary dry powder...
165 - MSGI Announces First Nanobeak Product -- Handheld Bloodless Diabetes Test
NEW YORK-(Business Wire)-September 23, 2009 - MSGI Security Solutions Inc. (OTCBB: MSGI) today reported that the Company is launching its first product derived from NASA technology, a handheld test for Diabetes, which uses breath instead of blood. Nanobeak Inc., an MSGI subsidiary, is a...
166 - KIKA Clinical Solutions Announces Veracity™ 3.7, New Version of Advanced EDC Solution for Clinical Trial Management
BOSTON & PARIS-(Business Wire)-September 23, 2009 - KIKA Clinical Solutions, the leading provider of advanced EDC solutions for clinical trials, continues leading the industry in providing solutions that go well beyond traditional EDC with the release of Veracity™ 3.7. Veracity™ is a...
167 - U.K. NICE Updates Clinical Guidelines to Support Use of Essure®
MOUNTAIN VIEW, Calif.-(Business Wire)-September 23, 2009 - Conceptus, Inc. (Nasdaq: CPTS), developer of the Essure procedure, the first proven non-incisional permanent birth control method available, today announced that the National Institute for Health and Clinical Excellence (NICE) in the...
168 - Abiomed Reports Results from Academic Medical Center’s Three-Year Follow-up of MACH II Trial
DANVERS, Mass.-(Business Wire)-September 23, 2009 - Abiomed Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced new clinical data from Academic Medical Center’s (AMC) three-year follow-up results from patients in the Impella 2.5 arm of the MACH II...
169 - Merck and QIAGEN Collaborate to Accelerate Access to Cervical Cancer Vaccination and Screening in Developing Countries
NEW YORK-(Business Wire)-September 23, 2009 - Merck & Co., Inc. and QIAGEN N.V. today announced their intent to collaborate on a new program to increase access to HPV vaccination and HPV DNA testing in some of the most resource-poor areas of the world. This initiative is the first time a vaccine...
170 - Bio-Computing a Major Focus of 22nd Annual SC Conference
PORTLAND, Ore.-(Business Wire)-September 23, 2009 - SC09, the 22nd annual supercomputing conference, recognized as the premier international conference on high performance computing (HPC), networking, storage and analysis, will offer presentations, seminars and panels featuring a world-class...
171 - American Diversified Holdings Corporation to Enter Stem Storage Business
DEL MAR, Calif.-(Business Wire)-September 23, 2009 - Ernest B. Remo, Chairman/CEO of American Diversified Holdings Corporation (Pink Sheets:ADHC), announced today that the company is currently in late stage negotiations with an established revenue producing company in the stem cell storage arena. It...
172 - Advanced BioHealing Outlines Strategic Growth Plan
WESTPORT, Conn.-(Business Wire)-September 23, 2009 - Advanced BioHealing, Inc. (ABH), a leader in commercializing the promise of regenerative medicine, announced a strategic growth plan designed to continue the transformation of this former start-up into the leading international regenerative...
173 - Genzyme Provides Update on Cerezyme and Fabrazyme Supply
CAMBRIDGE, Mass.-(Business Wire)-September 23, 2009 - Genzyme Corporation (NASDAQ: GENZ) today provided an update on its progress to restore supplies of Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta) for patients worldwide and revised its 2009 revenue guidance for these...
174 - Bio-Matrix Scientific Group and Therinject LLC Begin Development of Tumor Banking Facility in Conjunction with Cancer Therapeutic Vaccine
SAN DIEGO-(Business Wire)-September 23, 2009 - Bio-Matrix Scientific Group, Inc. (OTCBB: BMSN) announced today that the Company and Therinject LLC have begun development of a tumor banking facility. Tumor banking will allow storage and ease of sourcing for tumor cells to be utilized in cancer...
175 - Data Presented from Two Phase 3 ERBITUX® Studies in First-Line Metastatic Colorectal Cancer Patients at Joint 15th European Cancer Organisation and 34th European Society for Medical Oncology Multidisciplinary Congress
BERLIN-(Business Wire)-September 23, 2009 - According to a recent retrospective analysis of the pivotal Phase 3 CRYSTAL study, ERBITUX® (cetuximab), when added to FOLFIRI, was shown to increase median overall survival to 19.9 months in an intent-to-treat (ITT) population of first-line metastatic...
176 - Lux Biosciences Reports Phase 1 Safety Results and Open Label Efficacy Results for LX214, a Potential Best-in-Class Treatment for Dry Eye
JERSEY CITY, N.J.-(Business Wire)-September 23, 2009 - Lux Biosciences, Inc. a privately held biotechnology company focused on the treatment of ophthalmic diseases, today announced results from a Phase 1 human safety and an open-label pilot efficacy study of the company’s potential best-in-class...
177 - Aspect Magnet Technologies and Bruker BioSpin Establish a Collaborative Effort in Developing 1 Tesla Desktop MRI Solutions for New Preclinical MRI Applications
BEN SHEMEN, Israel & ETTLINGEN, Germany-(Business Wire)-September 23, 2009 - At the 2009 World Molecular Imaging Congress (WMIC) in Montreal, Aspect Magnet Technologies and Bruker BioSpin, a division of Bruker Corporation (NASDAQ: BRKR), today announced that they have signed a Memorandum of...
178 - Philips and Bruker BioSpin Sign Memorandum of Understanding to Bring New Imaging Technology to the Preclinical Market
MONTREAL-(Business Wire)-September 23, 2009 - At the 2009 World Molecular Imaging Congress (WMIC) in Montreal, Royal Philips Electronics (NYSE: PHG, AEX: PHI) and Bruker BioSpin, a division of Bruker Corporation (NASDAQ: BRKR), today announced that they have signed a memorandum of understanding...
179 - Philips and Celsion Advance Development of ThermoDox® and MR-Guided HIFU
ANDOVER, Mass. & COLUMBIA, Md.-(Business Wire)-September 23, 2009 - Royal Philips Electronics (NYSE: PHG; AEX: PHI) and Celsion Corporation (NASDAQ: CLSN) today announced that their joint research program to evaluate ThermoDox® in combination with MR-HIFU (Magnetic Resonance guided High...
180 - Opexa Triggers Milestone Payment Under Recently Announced Stem Cell Agreement
THE WOODLANDS, Texas-(Business Wire)-September 23, 2009 - Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing Tovaxin®, a personalized T-cell immunotherapy for multiple sclerosis (MS), today announced that it has achieved its first technology transfer milestone in connection with the...
181 - Lifeline Biotechnologies Updates Pink Sheets
RENO, Nev.-(Business Wire)-September 23, 2009 - Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO) today announced that it is preparing to establish a demonstration site for its First Warning System™ to be located in Reno, Nevada. Jim Holmes, Lifeline’s CEO, said, “We have filed the...
182 - Elixir Medical Corporation Announces Positive First-In-Man Results for Three Drug Eluting Coronary Stent Systems with Durable and Bioabsorbable Polymers
SUNNYVALE, Calif. & SAN FRANCISCO-(Business Wire)-September 23, 2009 - Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today positive results from three multicenter first-in-man studies of NovolimusTM...
183 - ImmunoCellular Therapeutics Announces Successful Humanization of Two Antibody Candidates
LOS ANGELES-(Business Wire)-September 23, 2009 - ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it has completed humanization of ICT-37 and ICT-109...
184 - CombinatoRx Stock Trading Halted Today; FDA Advisory Committees Meet to Discuss Exalgo
CAMBRIDGE, Mass. & VANCOUVER-(Business Wire)-September 23, 2009 - CombinatoRx, Incorporated (NASDAQ: CRXX) announced that NASDAQ has halted trading in the Company’s common stock today. The U.S. Food and Drug Administration’s (FDA) Anesthetics and Life Support Advisory Committee and its...
185 - Pluristem Therapeutics Doses First Patient in U.S. With Placenta-Derived Stem Cell Product PLX-PAD in a Phase I Clinical Trial for Treatment of Peripheral Artery Disease
HAIFA, Israel-(Business Wire)-September 23, 2009 - Pluristem Therapeutics Inc. (NasdaqCM: PSTI; DAX: PJT) today announced the dosing of the first patient in the U.S. with its placenta-derived stem cell product, PLX-PAD, the Company’s leading candidate, in a Phase I clinical trial for the treatment...
186 - Humedica’s Next-Generation Clinical Informatics Platform Offers Unparalleled Insight across the Health Care Continuum
BOSTON-(Business Wire)-September 23, 2009 - Humedica, a next-generation health care informatics company, today announced the company’s official launch, along with the previous completion of its $30 million round of venture capital and the roll-out of its ground-breaking clinical analytics...
187 - Idera Pharmaceuticals Presents Interim Data from Phase 1b Clinical Trial of IMO-2055 in Combination with Tarceva® and Avastin® in Non-Small Cell Lung Cancer
CAMBRIDGE, Mass.-(Business Wire)-September 23, 2009 - Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small...
188 - Plexxikon Announces Encouraging Data from Phase 1 Extension Study of PLX4032 Showing Objective Responses in Metastatic Melanoma Patients
BERLIN, Germany & BERKELEY, Calif.-(Business Wire)-September 23, 2009 - Plexxikon Inc. today announced encouraging clinical data from a Phase 1 extension study of PLX4032 (RG7204) in metastatic melanoma patients, which expand the results announced from the initial phase of the study. PLX4032...
189 - Labcyte Signs Bioscreen Instruments as Exclusive Distributor in India
SUNNYVALE, Calif. & CHENNAI, India-(Business Wire)-September 23, 2009 - Labcyte, the developer of acoustic liquid transfer, with systems in all top 10 pharmaceutical companies, today announced the selection of Bioscreen Instruments Pvt. Ltd. as its exclusive distributor in India. “Bioscreen is...
190 - Bruker Corporation Announces Pricing of Secondary Offering
BILLERICA, Mass.-(Business Wire)-September 23, 2009 - Bruker Corporation (NASDAQ: BRKR) today announced the pricing of an underwritten secondary offering of 13,000,000 shares of its common stock at a price to the public of $9.85 per share. The offering by the two selling stockholders, members of the...
191 - BioTime, Inc. to Form Asian Subsidiary
BEIJING & ALAMEDA, Calif.-(Business Wire)-September 23, 2009 - BioTime, Inc. (OTCBB:BTIM) announced today that it will organize a new subsidiary, BioTime Asia, Limited, for the purpose of clinically developing and marketing therapeutic stem cell products in the People’s Republic of China...
192 - Spectrum Pharmaceuticals Receives $50 Million from Institutional Investors at $7.55 Per Share
IRVINE, Calif.-(Business Wire)-September 22, 2009 - Spectrum Pharmaceuticals, Inc. (NasdaqGM:SPPI), a commercial-stage biotechnology company with a focus primarily in oncology, today announced that it has received $50 million from existing institutional investors in a previously announced registered...
193 - BioSante Pharmaceuticals and Cell Genesys Announce Final Exchange Ratio for Merger
LINCOLNSHIRE, Ill. & SOUTH SAN FRANCISCO, Calif.-(Business Wire)-September 22, 2009 - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) and Cell Genesys, Inc. (NASDAQ: CEGE), today announced that they have determined the final exchange ratio as 0.1828 in connection with the previously announced...
194 - BioSante Pharmaceuticals and Cell Genesys Announce Final Exchange Ratio for Merger
LINCOLNSHIRE, Ill. & SOUTH SAN FRANCISCO, Calif.-(Business Wire)-September 22, 2009 - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) and Cell Genesys, Inc. (NASDAQ: CEGE), today announced that they have determined the final exchange ratio as 0.1828 in connection with the previously announced...
195 - Emergent Health Corp. (EMGE) Expects to Revolutionize Vitamin Formulas
KING OF PRUSSIA, Pa.-(Business Wire)-September 22, 2009 - Emergent Health Corp. (Other OTC: EMGE) — Emergent expects to revolutionize the vitamin business. The company plans to introduce an adjuvant formula that enhances existing vitamin products currently on the market to assist in the...
196 - Incyte Announces Proposed Public Offering of 18,000,000 Shares of Common Stock
WILMINGTON, Del.-(Business Wire)-September 22, 2009 - Incyte Corporation (Nasdaq:INCY) today announced that it intends to offer to sell, subject to market and other conditions, 18,000,000 shares of its common stock in an underwritten public offering. In connection with the offering, the Company...
197 - Transoma Medical Enrolls First Patient in Clinical Study Comparing Use of External Recorders with Implantable Monitors to Track Recurrence of Atrial Fibrillation
ST. PAUL, Minn.-(Business Wire)-September 22, 2009 - Transoma Medical, Inc., manufacturer of Sleuth AT™, the only wireless, automated implantable cardiac monitoring system with programmable and frequent electrocardiogram (ECG) sampling, announced today the first enrollment and implant in the...
198 - Worldwide Health Director for Microsoft to Deliver Luncheon Keynote Address at the 8th Annual LifeScience Alley® Conference & Expo
MINNEAPOLIS-(Business Wire)-September 22, 2009 - Dr. Bill Crounse, senior director of worldwide health for the Microsoft Corporation, will deliver the luncheon keynote address at the 8th Annual LifeScience Alley Conference & Expo on December 9 at the Minneapolis Convention Center. In his...
199 - SuperGen to Present at UBS Life Sciences Conference at New Time of 8:30 am Eastern September 23rd
DUBLIN, Calif.-(Business Wire)-September 22, 2009 - SuperGen, Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that James S.J. Manuso, Ph.D., President and Chief Executive Officer, and Michael McCullar, Ph.D., Vice...
200 - Top 20 Pharma Firms to Hunt for Deals at BIO-Europe 2009
ZURICH & VIENNA-(Business Wire)-September 22, 2009 - In order to seek out new partnering opportunities, the top 20 big pharma companies will be in attendance on November 2–4 in Vienna, Austria for BIO-Europe 2009, the largest dedicated partnering conference in Europe. Teams of scouts from...
Search Our News Using Google Search
Can't find what you want? Try using Google:
